VACCINES & ANTIBIOTIC MANUFACTURING

 

 

Vaccines can play key role in combatting the spread of resistance, yet they have been a historically under recognized as a tool for fighting AMR. Hear from biotechs, pharmaceutical companies and funders on both the integration of vaccines into AMR strategies, as well as innovative vaccine development.

 

Antibiotic manufacturing has several key components impacting the spread of resistance: product quality, waste management and sustainable supply chains. These key elements affect both the efficiency for the manufacturer and also the spread of antimicrobial waste in the environment. Hear from large pharma, generic manufacturers, biotechs, and CMOs/CDMOs on how to improve manufacturing processes to
prevent antimicrobial resistance.

 

Manufacturing, Thursday 7 November 2019

Conference Registration

Concrete Commercial Initiatives

Jonathan Van-Tam
08:40

Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics

09:20

Sponsored keynote address

TITLE SPONSOR SLOT
10:20

SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK

Supply Chain

Jaideep Gogtay
Manufacturing
11:15

Ensuring a sustained availability of high-quality antibiotics - Considerations for manufacturing, quality testing, transport, poor quality drugs, and the role of customers

Alba Tiley
Manufacturing
11:35

Collaborating along the value chain for sustainably-made antibiotics: roles of manufacturers and buyers

Jacques Dumas
Manufacturing
11:55

Synthesizing complex molecules for antibacterial products – manufacturing challenges and opportunities

Manufacturing
12:15

GOLD SPONSOR SESSION

If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com.

12:35

Networking Lunch Break

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Christine Årdal
14:10

Roundtable 10 Market Access - overcoming access barriers for smaller markets - considerations for countries and developers

Christian Lillis
14:10

Roundtable 11 Patient Advocacy - what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiativ

Marco Taglietti
14:10

Roundtable 12 Candida auris - a ticking time bomb: responding to an urgent global public health threat

Dave Ousterout
14:10

Roundtable 13 Phage development - Opportunities in development of novel phage therapies

Debbie Goff
14:10

Roundtable 14 Global collaboration – global stakeholder collaboration between clinicians, policy makers, pharmaceutical/diagnostic companies is needed to succeed at ASP

Amy Kirby
14:10

Roundtable 15 Water Quality – understanding transmission of waterborne pathogens and how the international community can combat the spread of resistance through integrating advanced lab techniques

Jeffrey Cies
14:10

Roundtable 16 Drug dosing – anti-infective underdosing and opportunities for customized drug dosing

Kartik Cherabuddi
14:10

Roundtable 2 Controlling c.dif - determining who to test and how to prevent additional outbreaks in the hospital

Richard Vickers
14:10

Roundtable 3 Innovation & stewardship - Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship.

Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes.
Justine Ross
14:10

Roundtable 4 Customizing Epic – the use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center

Colm Leonard
14:10

Roundtable 5 Antimicrobial value assessment - a look into the role of HTA in the UK's testing of novel assessment and delinked payment program

Jay K Varma
14:10

Roundtable 6 Policy in Africa- advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans

Brian Tse
14:10

Roundtable 7 Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical development

Ryan Devies
14:10

Roundtable 8 Advancing Preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugs

Jane Knisely
14:10

Roundtable 9 Supporting development - NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening

NIH programs filling the gaps in traditional and non-traditionaltherapeutic discovery & development with grants, contracts,in-vitro and in vivo screening and manufacturing capabilities and more.

Waste Management

Steve Brooks
Manufacturing
15:15

Update on AMR and environmental manufacturing

Dale L Stemple
Manufacturing
15:35

Future outlook & best practices for manufacturing to reduce AMR: sustainable frameworks and emerging technologies

Jason Snape
Manufacturing
15:55

Challenges with assessing and managing the environmental risks of antibiotics and AMR

Speaker to be announced.
Manufacturing
16:15

GOLD SPONSOR SESSION

If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at+1 646 619 1797 or andre.singer@terrapinn.com.
16:35

Networking coffee break

Supported by BD

18:15

Drinks Reception

Thomas Cueni
18:15

Welcoming remarks by AMR Industry Alliance

Cocktail Reception hosted by AMR Industry Alliance
last published: 11/Oct/19 22:05

Vaccines in AMR, Friday 8 November 2019

08:00

Conference Registration

Tom Lowery
09:25

Keynote Address: The impact of rapid, direct-from-blood diagnostics in enabling changes in clinical decisions and improving outcomes

10:30

Networking coffee break

Uptake and prevention

James Wassil
Vaccines in AMR
11:15

Linking vaccine use to AMR reduction – Do we have enough evidence to convince policy makers to incorporate vaccines into broader AMR strategies

Allison Flinn
Vaccines in AMR
11:35

The role of vaccination in Antimicrobial Stewardship (AMS) and Merck’s One Health approach to tackling the challenge of AMR

M Javad Aman
Vaccines in AMR
11:55

A novel toxoid vaccine targeting Staphylococcus aureus virulence

Jacqueline Miller
Vaccines in AMR
12:15

An Established Tool to Address New Challenges in Anti-Microbial Resistance

12:35

Networking Lunch Break

13:40

Networking Lunch Break Resumes

ROUNDTABLES (1-hour roundtable sessions split between 2 rounds of 30min)

Clifford Mcdonald
14:10

Roundtable 10 Microbiome & CDC – Discussing a vision for precision public health novel approaches to treating infection prevention through the microbiome

Minh-Hong Nguyen
14:10

Roundtable 11 Developing diagnostics – novel approaches to development

Minh-Hong Nguyen, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, University of Pittsburgh
Courtney Jones
14:10

Roundtable 12 Infection intervention – using the microbiome to make antibiotics effective again

Mary Millard
14:10

Roundtable 13 Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices

Wes Kim
14:10

Roundtable 14 SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

Jomana Musmar
14:10

Roundtable 15 One Health - The Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) recommending federal One Health action to address AMR

Sarah De Clercq
14:10

Roundtable 16 AMR in Belgium – Creating a one health National Action Plan on AMR – rollout and next steps

Sumathi Nambiar
14:10

Roundtable 17 FDA Roundtable discussion

Nick Van Hise
14:10

Roundtable 2 The fecal microbiome - new approaches to the treatment of C. difficile infection

Eugean Jiwanmall
14:10

Roundtable 3 Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensus

Thomas Heymann
14:10

Roundtable 4 AMR and Sepsis - we are all in this together

Eili Klein
14:10

Roundtable 5 Surveillance

Examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR.
Angella Browne
14:10

Roundtable 7 Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and more

Jeanette Mucha
14:10

Roundtable 8 CARB-X Accelerator – Company perspective on CARB-X Accelerator - What worked and what can be improved?

Abigail Colson
14:10

Roundtable 9 Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem?

Wes Kim
14:10

Roundtable: SPARK Platform: Pew Charitable Trusts’ Collaborative Discovery Tool for Gram-Negative Antibiotics

last published: 11/Oct/19 22:05

 

 


GET INVOLVED AT

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


André Singer
andre.singer@terrapinn.com
+1 646.619.1797

 

 

Press & Media Partnerships

 


Shannon McGorry
shannon.mcgorry@terrapinn.com
+1 646.619.1840

 

 

To Speak

 


Claire Murphy
claire.murphy@terrapinn.com
+1 646.619.1784

 

Sign Up for Event Updates